Neurogene has a $903M market cap with two phase 1/2 assets, NGN-401 for Rett Syndrome and NGN-101 for CLN5 Batten Disease.
A research team has established a virus-induced gene silencing (VIGS) system in taro, enabling researchers to rapidly verify ...
Purespring’s gene therapy, PS-002, uses a viral vector to target kidney cells—known as podocytes—to treat IgA nephropathy, a ...
The gene therapy improved annualized bleed rates, though a handful of study participants resumed factor IX prophylaxis.
With the formation of a new strategic partnership, Dyno Therapeutics is responsible for the development of novel AAV capsids.
Continuing their journey to develop a vaccine for HIV, Oregon Health & Science University researchers have identified a gene ...
Adeno-associated viral vectors (AAV) have emerged as key players in this growth trajectory, projected to capture a ...
In this GEN webinar, Andrea O'Hara, PhD, a multiomics expert at GENEWIZ from Azenta Life Sciences, will discuss how to use ...
Dyno Therapeutics has recently announced the formation of a new strategic partnership with Swiss pharma giant Roche to ...
RCCS San Raffaele Scientific Institute in Milan researchers have discovered that hematopoietic stem cells (HSCs) adapt their lineage commitment during gene therapy based on the underlying genetic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback